vs
博士伦（BLCO）与Healthpeak Properties（DOC）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Healthpeak Properties的2.0倍（$1.4B vs $719.4M），Healthpeak Properties净利率更高（73.2% vs -4.1%，领先77.3%），博士伦同比增速更快（9.8% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs 8.9%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
BLCO vs DOC — 直观对比
营收规模更大
BLCO
是对方的2.0倍
$719.4M
营收增速更快
BLCO
高出6.7%
3.1%
净利率更高
DOC
高出77.3%
-4.1%
自由现金流更多
DOC
多$297.0M
$60.0M
两年增速更快
BLCO
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $719.4M |
| 净利润 | $-58.0M | $114.0M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 17.4% |
| 净利率 | -4.1% | 73.2% |
| 营收同比 | 9.8% | 3.1% |
| 净利润同比 | -1833.3% | 2406.4% |
| 每股收益（稀释后） | $-0.16 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCODOC
| Q4 25 | $1.4B | $719.4M | ||
| Q3 25 | $1.3B | $705.9M | ||
| Q2 25 | $1.3B | $694.3M | ||
| Q1 25 | $1.1B | $702.9M | ||
| Q4 24 | $1.3B | $698.0M | ||
| Q3 24 | $1.2B | $700.4M | ||
| Q2 24 | $1.2B | $695.5M | ||
| Q1 24 | $1.1B | $606.6M |
净利润BLCODOC
| Q4 25 | $-58.0M | $114.0M | ||
| Q3 25 | $-28.0M | $-117.1M | ||
| Q2 25 | $-62.0M | $31.7M | ||
| Q1 25 | $-212.0M | $42.8M | ||
| Q4 24 | $-3.0M | $4.5M | ||
| Q3 24 | $4.0M | $85.9M | ||
| Q2 24 | $-151.0M | $146.0M | ||
| Q1 24 | $-167.0M | $6.7M |
毛利率BLCODOC
| Q4 25 | — | — | ||
| Q3 25 | — | 58.6% | ||
| Q2 25 | — | 60.2% | ||
| Q1 25 | — | 61.1% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | — | 60.0% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 59.8% |
营业利润率BLCODOC
| Q4 25 | 8.0% | 17.4% | ||
| Q3 25 | 7.4% | 9.2% | ||
| Q2 25 | -0.9% | 5.7% | ||
| Q1 25 | -7.3% | 7.7% | ||
| Q4 24 | 6.8% | -2.2% | ||
| Q3 24 | 3.6% | 14.1% | ||
| Q2 24 | 2.1% | 22.3% | ||
| Q1 24 | 0.5% | 3.7% |
净利率BLCODOC
| Q4 25 | -4.1% | 73.2% | ||
| Q3 25 | -2.2% | -16.6% | ||
| Q2 25 | -4.9% | 4.6% | ||
| Q1 25 | -18.6% | 6.1% | ||
| Q4 24 | -0.2% | 0.7% | ||
| Q3 24 | 0.3% | 12.3% | ||
| Q2 24 | -12.4% | 21.0% | ||
| Q1 24 | -15.2% | 1.1% |
每股收益（稀释后）BLCODOC
| Q4 25 | $-0.16 | $0.16 | ||
| Q3 25 | $-0.08 | $-0.17 | ||
| Q2 25 | $-0.18 | $0.05 | ||
| Q1 25 | $-0.60 | $0.06 | ||
| Q4 24 | $-0.00 | $0.02 | ||
| Q3 24 | $0.01 | $0.12 | ||
| Q2 24 | $-0.43 | $0.21 | ||
| Q1 24 | $-0.48 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $467.5M |
| 总债务越低越好 | $5.0B | $9.8B |
| 股东权益账面价值 | $6.4B | $7.5B |
| 总资产 | $14.0B | $20.3B |
| 负债/权益比越低杠杆越低 | 0.78× | 1.31× |
8季度趋势，按日历期对齐
现金及短期投资BLCODOC
| Q4 25 | $383.0M | $467.5M | ||
| Q3 25 | $310.0M | $91.0M | ||
| Q2 25 | $266.0M | $89.4M | ||
| Q1 25 | $202.0M | $70.6M | ||
| Q4 24 | $305.0M | $119.8M | ||
| Q3 24 | $329.0M | $180.4M | ||
| Q2 24 | $285.0M | $106.9M | ||
| Q1 24 | $315.0M | $101.8M |
总债务BLCODOC
| Q4 25 | $5.0B | $9.8B | ||
| Q3 25 | $5.0B | $9.1B | ||
| Q2 25 | $5.0B | $9.0B | ||
| Q1 25 | $4.8B | $8.9B | ||
| Q4 24 | $4.8B | $8.7B | ||
| Q3 24 | $4.6B | $8.6B | ||
| Q2 24 | $4.6B | $8.6B | ||
| Q1 24 | $4.6B | $8.8B |
股东权益BLCODOC
| Q4 25 | $6.4B | $7.5B | ||
| Q3 25 | $6.4B | $7.6B | ||
| Q2 25 | $6.4B | $7.9B | ||
| Q1 25 | $6.4B | $8.2B | ||
| Q4 24 | $6.5B | $8.4B | ||
| Q3 24 | $6.6B | $8.6B | ||
| Q2 24 | $6.5B | $8.8B | ||
| Q1 24 | $6.7B | $8.9B |
总资产BLCODOC
| Q4 25 | $14.0B | $20.3B | ||
| Q3 25 | $13.8B | $19.6B | ||
| Q2 25 | $13.8B | $19.8B | ||
| Q1 25 | $13.4B | $19.8B | ||
| Q4 24 | $13.5B | $19.9B | ||
| Q3 24 | $13.5B | $20.0B | ||
| Q2 24 | $13.3B | $20.2B | ||
| Q1 24 | $13.3B | $20.5B |
负债/权益比BLCODOC
| Q4 25 | 0.78× | 1.31× | ||
| Q3 25 | 0.77× | 1.20× | ||
| Q2 25 | 0.77× | 1.14× | ||
| Q1 25 | 0.76× | 1.08× | ||
| Q4 24 | 0.74× | 1.04× | ||
| Q3 24 | 0.70× | 1.00× | ||
| Q2 24 | 0.71× | 0.98× | ||
| Q1 24 | 0.69× | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $357.0M |
| 自由现金流率自由现金流/营收 | 4.3% | 49.6% |
| 资本支出强度资本支出/营收 | 5.4% | 124.4% |
| 现金转化率经营现金流/净利润 | — | 10.99× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | — |
8季度趋势，按日历期对齐
经营现金流BLCODOC
| Q4 25 | $136.0M | $1.3B | ||
| Q3 25 | $137.0M | $315.0M | ||
| Q2 25 | $35.0M | $363.5M | ||
| Q1 25 | $-25.0M | $279.4M | ||
| Q4 24 | $22.0M | $1.1B | ||
| Q3 24 | $154.0M | $318.2M | ||
| Q2 24 | $15.0M | $316.2M | ||
| Q1 24 | $41.0M | $152.6M |
自由现金流BLCODOC
| Q4 25 | $60.0M | $357.0M | ||
| Q3 25 | $63.0M | — | ||
| Q2 25 | $-54.0M | — | ||
| Q1 25 | $-135.0M | — | ||
| Q4 24 | $-70.0M | $333.7M | ||
| Q3 24 | $94.0M | — | ||
| Q2 24 | $-57.0M | — | ||
| Q1 24 | $-26.0M | — |
自由现金流率BLCODOC
| Q4 25 | 4.3% | 49.6% | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -11.9% | — | ||
| Q4 24 | -5.5% | 47.8% | ||
| Q3 24 | 7.9% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | -2.4% | — |
资本支出强度BLCODOC
| Q4 25 | 5.4% | 124.4% | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 7.2% | 105.6% | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 6.1% | — |
现金转化率BLCODOC
| Q4 25 | — | 10.99× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 11.48× | ||
| Q1 25 | — | 6.52× | ||
| Q4 24 | — | 235.43× | ||
| Q3 24 | 38.50× | 3.71× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | — | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
DOC
暂无分部数据
